Arcus Development Group Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Arcus Development Group in den nächsten Jahren?
Pro
?
U****************
?
M****
?
M************
Kontra
?
A****************
?
L*********** I********** f** d** n******* J****
?
W******* i* V********
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Arcus Development Group im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Arcus Development Group | - | - | - | - | - | - | - |
| Zonte Metals Inc. | -9,32 % | -15,08 % | 64,62 % | 224,24 % | 100,00 % | 73,98 % | -7,76 % |
| TomaGold Corp | 6,98 % | -17,12 % | 87,76 % | 338,10 % | 87,76 % | 113,95 % | 1,10 % |
| Golconda Gold Ltd. | -1,79 % | -2,80 % | 26,83 % | - | 32,48 % | - | - |
Kommentare
News
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return
On Dec. 4, 2025, Juan C. Jaen, President of Arcus Biosciences (NYSE:RCUS), disposed of 82,997 shares in an open-market transaction via an indirect holding, generating a transaction value of
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan
Juan C. Jaen, the president of Arcus Biosciences (NYSE:RCUS), sold 96,859 shares in multiple open-market transactions on Tuesday and Wednesday, according to an SEC Form 4 filing.
The transaction
Arcus (RCUS) Q2 Revenue Jumps 310%
Arcus Biosciences (NYSE:RCUS), a clinical-stage biotech focused on cancer immunotherapies, reported its second-quarter 2025 earnings on August 6, 2025. GAAP revenue and earnings per share both